Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
CONCLUSION: Sorafenib appears to be an effective maintenance therapy after allo-HCT in FLT3-ITD AML, with achievement of durable complete responses. This suggests an immunomodulatory effect of sorafenib in the posttransplantation setting and warrants a broader clinical evaluation of the use of maintenance sorafenib in FLT3-ITD AML.
PMID: 25550214 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A Tags: Clin Lymphoma Myeloma Leuk Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Corticosteroid Therapy | Genetics | Heart Attack | Leukemia | Lymphoma | Myeloma | Skin | Skin Graft | Transplants